Tafenoquine and ACTs (TADORE- Plus)
ConditionVivax Malaria
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorMenzies School of Health Research
About this trial
A trial designed to determine whether there is a clinically significant drug-drug interaction of tafenoquine with DHA-piperaquine or artesunate-pyronaridine using a control arm with radical cure given at the end of follow up (delayed radical cure).
Eligibility criteria
Qualifiers
P. vivax peripheral parasitaemia (mono-infection)
G6PD normal status (G6PD activity ≥70% of the adjusted male median
as determined by the Standard G6PD (SD Biosensor, ROK))
Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours
Disqualifiers
Danger signs or symptoms of severe malaria
Pregnant or lactating females
Regular use of drugs with haemolytic potential
Known hypersensitivity to any of the study drugs
Trial design
Treatments tested in this trial
- Tafenoquine plus DHA-Piperaquine
- Tafenoquine plus Artesunate-pyronaridine
Treatment groups
507 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov